Synthesis of Sorafenib−Ruthenium Complexes, Investigation of Biological Activities and Applications in Drug Delivery Systems as an Anticancer Agent
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c01115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Belma Zengin Kurt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Bezmialem Vakif University, 34093 Istanbul, Türkiye. Hauptthemen laut MEDLINE: Ruthenium, Liver Neoplasms, Antineoplastic Agents, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu.
Abstract (Originalsprache)
Sorafenib, a multiple kinase inhibitor, is widely used as a first-line treatment for hepatocellular carcinoma. However, there is a need for more effective alternatives when sorafenib proves insufficient. In this study, we aimed to design a structure that surpasses sorafenib's efficacy, leading us to synthesize sorafenib-ruthenium complexes for the first time and investigate their properties. Our results indicate that the sorafenib-ruthenium complexes exhibit superior epidermal growth factor receptor (EGFR) inhibition compared to sorafenib alone. Interestingly, among these complexes, Ru3S demonstrated high activity against various cancer cell lines including sorafenib-resistant HepG2 cells while exhibiting significantly lower cytotoxicity than sorafenib in healthy cell lines. Further evaluation of cell cycle, cell apoptosis, and antiangiogenic effects, molecular docking, and molecular dynamics studies revealed that Ru3S holds great potential as a drug candidate. Additionally, when free Ru3S was encapsulated into polymeric micelles M1, enhanced cytotoxicity on HepG2 cells was observed. Collectively, these findings position Ru3S as a promising candidate for EGFR inhibition and warrant further exploration for drug development purposes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Bezmialem Vakif University, 34093 Istanbul, Türkiye.
- Faculty of Pharmacy, Department of Pharmacology, Bezmialem Vakif University, 34093 Istanbul, Türkiye.
- Institute of Science, Sakarya University, 34000 Sakarya, Türkiye.
- Faculty of Science, Department of Chemistry, Karadeniz Technical University, 61080 Trabzon, Türkiye.
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Anadolu University, 26470 Eskişehir, Türkiye.
- Badakbas Pharmacy, Altintepe str. Koknarli 6/C, Maltepe, 34840 Istanbul, Türkiye.
ORCID-Profile: Belma Zengin Kurt, Dilek Öztürk Civelek, Begüm Nurpelin Sağlık Özkan, Aydan Dag
Förderung
- T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu
Zitieren
APA
Zengin Kurt, B., Öztürk Civelek, D., Çakmak, E. B., Kolcuoğlu, Y., Şenol, H., Sağlık Özkan, B. N., Dag, A., & Benkli, K. (2024). Synthesis of Sorafenib−Ruthenium Complexes, Investigation of Biological Activities and Applications in Drug Delivery Systems as an Anticancer Agent. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01115
Vancouver
Zengin Kurt B, Öztürk Civelek D, Çakmak EB, Kolcuoğlu Y, Şenol H, Sağlık Özkan BN, et al. Synthesis of Sorafenib−Ruthenium Complexes, Investigation of Biological Activities and Applications in Drug Delivery Systems as an Anticancer Agent. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01115
BibTeX
@article{ZenginKurt2024,
author = {Zengin Kurt, Belma and Öztürk Civelek, Dilek and Çakmak, Elmas Begüm and Kolcuoğlu, Yakup and Şenol, Halil and Sağlık Özkan, Begüm Nurpelin and Dag, Aydan and Benkli, Kadriye},
title = {Synthesis of Sorafenib−Ruthenium Complexes, Investigation of Biological Activities and Applications in Drug Delivery Systems as an Anticancer Agent},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c01115}
}
EUVIMED